Autoimmune neurologic diseases

Oral

B Cell Subsets as Potential Biomarkers for Fingolimod Treatment in Multiple Sclerosis (ms)

Friday, June 16
6:15 PM - 7:30 PM

Several S1P-receptor functional antagonists are being pursued for the treatment of MS, with fingolimod approved as first-in-class in 2010. While many patients become free of new brain lesions and clinical relapses (Stable), a proportion of patients continue to develop new disease activity (Active) in spite of ongoing treatment. In this study, we aimed to identify a potential predictive biomarker to distinguish such Active versus Stable patients in a prospectively followed cohort of 33 RRMS patients receiving clinically-indicated fingolimod treatment. Patients were ascertained as either Active (n=17) or Stable (n=16) based on whether they did, or did not, develop new T2 brain MRI lesions and/or clinical relapses over 2 years of treatment. High quality PBMC were collected pre- and post-fingolimod and interrogated in-batch using 18-colour flow cytometry panels to functionally immune-phenotype over 80 immune-cell subsets. As expected, circulating counts of all major lymphocyte populations decreased substantially on-treatment, in both groups. While counts of T cell, myeloid cell and NK cell subsets did not differ pre-fingolimod between the two groups, B cell counts were significantly higher in the Active group at baseline (p=0.0066), mainly reflecting increased numbers of mature (p=0.0061) but not transitional (p=0.6233) B cells. Among mature B cells, both pro- and anti-inflammatory cytokine-defined B cell subsets were increased in the Active group, suggesting a more general active phenotype of these B cells in patients destined to experience continued disease activity on-treatment. Our data identify mature B-cell counts as a potential predictive biomarker of fingolimod treatment-response in RRMS patients.

Rui Li

Post-doc
University of Pennsylvania

Presentation(s):

    Send Email for Rui Li

    Mathab Ghadiri

    Montreal Neurological Institute, McGill University

    Presentation(s):

      Send Email for Mathab Ghadiri

      Ayman Rezk

      Ph.D Candidate
      Montreal Neurological Institute, McGill University

      Presentation(s):

        Send Email for Ayman Rezk

        Paul Giacomini

        Montreal Neurological Institute, McGill University

        Presentation(s):

          Send Email for Paul Giacomini

          Jack Antel

          Professor
          McGill University, Montreal Neurological Institute

          Presentation(s):

            Send Email for Jack Antel

            Amit Bar-Or

            Melissa and Paul Anderson President’s Distinguished Professor
            University of Pennsylvania and McGill University

            Presentation(s):

              Send Email for Amit Bar-Or


              Assets

              B Cell Subsets as Potential Biomarkers for Fingolimod Treatment in Multiple Sclerosis (ms)



              Attendees who have favorited this

              Send Email for B Cell Subsets as Potential Biomarkers for Fingolimod Treatment in Multiple Sclerosis (ms)